Holen Sie sich die Stockscreener-App
1.70
3.66%
0.06
Handel nachbörslich:
1.73
0.03
+1.76%
Schlusskurs vom Vortag:
$1.64
Offen:
$1.64
24-Stunden-Volumen:
1.59M
Relative Volume:
1.48
Marktkapitalisierung:
$184.16M
Einnahmen:
$27.08M
Nettoeinkommen (Verlust:
$-37.00M
KGV:
-3.2692
EPS:
-0.52
Netto-Cashflow:
$-18.46M
1W Leistung:
+9.68%
1M Leistung:
+8.28%
6M Leistung:
-22.73%
1J Leistung:
+42.86%
1-Tages-Spanne:
$1.63
$1.77
1-Wochen-Bereich:
$1.52
$1.77
52-Wochen-Spanne:
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Firmenname
Aclaris Therapeutics Inc
Sektor
Branche
Telefon
484-324-7933
Adresse
701 LEE ROAD, WAYNE, PA
Vergleichen Sie ACRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.70 | 177.58M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-05-28 | Eingeleitet | Wedbush | Outperform |
| 2025-03-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-11-19 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Eingeleitet | Evercore ISI | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-10-06 | Eingeleitet | BTIG Research | Buy |
| 2021-07-23 | Fortgesetzt | Jefferies | Buy |
| 2021-06-15 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-10-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Eingeleitet | SVB Leerink | Outperform |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-09 | Eingeleitet | Guggenheim | Buy |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Eingeleitet | Leerink Partners | Outperform |
| 2016-09-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-06-10 | Eingeleitet | Guggenheim | Buy |
| 2015-11-02 | Eingeleitet | Citigroup | Buy |
| 2015-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Aclaris Therapeutics Reports Q2 Loss, Highlights Progress in Immuno-Dermatology Pipeline - MSN
Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Earnings Beat: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - uk.finance.yahoo.com
Aclaris Therapeutics Reports Q2 2025 Earnings, Highlights Clinical Advancements and Financial Metrics. - AInvest
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates - MSN
Aclaris Reports Positive Phase 2a Results for ATI-2138 in Atopic Dermatitis Trial - MSN
Aclaris Therapeutics Reports Q2 2025 Results and Updates - TipRanks
Ati Inc. shares rise 2.39% premarket after Aclaris Therapeutics reported positive clinical results from Phase 2a trial of ITK/JAK3 inhibitor ATI-2138. - AInvest
Aclaris: Q2 Earnings Snapshot - The Washington Post
Aclaris Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aclaris Therapeutics reports Q2 EPS (13c), consensus (13c) - TipRanks
Aclaris Therapeutics Inc earnings beat by $0.01, revenue topped estimates - Investing.com India
Aclaris Therapeutics shares rise 3.23% premarket after reporting Q2 earnings that met Wall Street expectations. - AInvest
Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Leerink Partners Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Relief Rally in Aclaris Therapeutics Inc. Stock — Can It HoldFree Membership Group - beatles.ru
What drives Aclaris Therapeutics Inc. stock priceMaximize your returns with smart trade entries - Jammu Links News
Aclaris Therapeutics Taps Veteran Biotech Leader Roland Kolbeck as New Chief Scientific Officer - MSN
How many analysts rate Aclaris Therapeutics Inc. as a “Buy”Invest confidently with professional market insights - Jammu Links News
What are Aclaris Therapeutics Inc. company’s key revenue driversTriple-digit profit margins - Jammu Links News
Is Aclaris Therapeutics Inc. a growth stock or a value stockDiscover undervalued opportunities early - Jammu Links News
What is the dividend policy of Aclaris Therapeutics Inc. stockCapitalize on emerging market trends - Jammu Links News
Is Aclaris Therapeutics Inc. a good long term investmentCapitalize on market trends before they peak - Jammu Links News
What analysts say about Aclaris Therapeutics Inc. stockMarket-leading growth rates - Jammu Links News
What is the risk reward ratio of investing in Aclaris Therapeutics Inc. stockUnmatched profit potential - Jammu Links News
What are the latest earnings results for Aclaris Therapeutics Inc.Discover market opportunities with expert help - Jammu Links News
What catalysts could drive Aclaris Therapeutics Inc. stock higher in 2025Unlock powerful market analysis and alerts - Jammu Links News
Aclaris Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
How volatile is Aclaris Therapeutics Inc. stock compared to the marketBreakout Stocks Watchlist That Work - jammulinksnews.com
Is it the right time to buy Aclaris Therapeutics Inc. stockDaily Trading Report For Consistent Profits - Jammu Links News
Is Aclaris Therapeutics Inc. stock bottoming outTechnical Screener for High Growth Stocks - Newser
Is a relief rally coming for Aclaris Therapeutics Inc. holdersTechnical Stock Breakout Predictions Signal Entry Points - metal.it
Will Aclaris Therapeutics Inc. outperform the marketRisk Shielded Trade Watch with Analysis - Newser
Analysts Boost Healthcare Stocks: Aclaris Therapeutics and Nuvation Bio - AInvest
Aclaris Therapeutics Inc. Breaks Below Key Support LevelQuick Gain Stock Watch With Indicators Reviewed - metal.it
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Market reaction to Aclaris Therapeutics Inc.’s recent newsEntry Alert Based on Volume Spikes Detected - metal.it
Stock Market Today: US Future Edge Higher Ahead Of FOMC Decision—Meta, Microsoft Earnings In Focus - Benzinga
Momentum divergence signals in Aclaris Therapeutics Inc. chartAI Model Forecasting Reversal and Breakout Zones - Newser
Aclaris Therapeutics Stock Spikes In After‑Hours Session Following Major Announcement - Benzinga
Aclaris Therapeutics Announces Positive Top-Line Results - GlobeNewswire
Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):